61.91
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Sarepta price target lowered to $179 from $210 at BofA - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Shareholders to Learn More About the Investigation - markets.businessinsider.com
Sarepta Therapeutics (NASDAQ:SRPT) Lowered to “Sector Perform” Rating by Royal Bank of Canada - Defense World
RBC Capital Downgrades Sarepta Therapeutics (LSE:0L35) - Nasdaq
RBC Capital Downgrades Sarepta Therapeutics (SRPT) - MSN
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph
Sarepta's Aggressive Growth: 39 New Hires Receive Substantial Equity Package - Stock Titan
Top vaccine official’s ouster sends biotech stocks tumbling - The Boston Globe
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Why Sarepta Therapeutics (SRPT) Stock Is Nosediving - Yahoo Finance
Moderna Stock Sinks After Top FDA Official Resigns; Sarepta Gets Hit, Too. - MSN
RBC Capital Downgrades Sarepta Therapeutics (BMV:SRPT) - Nasdaq
Sarepta downgraded at RBC Capital on gene therapy concerns (SRPT:NASDAQ) - Seeking Alpha
Fiery Resignation of Top FDA Official Sparks Biotech Stock Selloff - Barron's
Sarepta Craters After RBC’s 45% Price Target Cut - Wall Street Pit
Drugmakers tumble on reports FDA's top vaccine regulator set to leave - MarketScreener
A recent gene therapy death shines a light on AAV safety - PharmaVoice
Biotech stocks tumble on reports FDA's top vaccine regulator to leave - MarketScreener
RBC Downgrades Sarepta Therapeutics to Sector Perform From Outperform, Adjusts PT to $87 From $161 - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph
Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy? - Yahoo Finance
Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday? - MSN
Dravet Gene Therapy Tested in Mice, Sarepta’s Setback, and AstraZeneca Updates - Genetic Engineering & Biotechnology News
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Safety Questions Loom in Duchenne as Dyne, Wave and Others Plan FDA Filings - BioSpace
Wave Aspires To Accelerated Approval In DMD With 48-Week Data - News & Insights
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Wave strengthens case for accelerated approval, with more positive Duchenne data - Endpoints News
Sarepta stock plunges to 52-week low, touches $73 By Investing.com - Investing.com South Africa
Sarepta stock plunges to 52-week low, touches $73 - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect - Markets Insider
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion - Nasdaq
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Is This Stock a Buy After a Massive 20% Drop in 1 Day? - Yahoo Finance
StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta - Genetic Engineering & Biotechnology News
PNC Financial Services Group Inc. Has $352,000 Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Scotiabank Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up - NewsBreak: Local News & Alerts
Nvidia, Nike, Sarepta Therapeutics, Protalix and more analyst calls of the week - Proactive Investors UK
This Is What Whales Are Betting On Sarepta Therapeutics - Benzinga
Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing - News & Insights
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Givi - Asianet Newsable
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 4% After Analyst Downgrade - Defense World
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance
HC Wainwright Reiterates “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT) - Defense World
Sarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT) - Defense World
Sarepta plunges after death linked to Elevidys (update) - MSN
Sarepta: Should Investors Run For The Exit? (NASDAQ:SRPT) - Seeking Alpha
Sarepta Therapeutics’ stock falls after patient dies of liver failure - MSN
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More - Zacks Investment Research
Regenxbio Rises After Duchenne Update And Sarepta Safety Scare - News & Insights
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation - Markets Insider
Sarepta Therapeutics stock falls after DMM patient dies of liver failure - MSN
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades - PharmaVoice
In Wake of Elevidys Death, Duchenne Patient Community Vows to Push On - BioSpace
Sarepta Therapeutics (NASDAQ:SRPT) Given New $99.00 Price Target at Deutsche Bank Aktiengesellschaft - Armenian Reporter
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):